Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
Spinraza
Description:
A brand name for nusinersen, an antisense oligonucleotide medicine used to treat spinal muscular atrophy.
Primary topic:
Neurogenetic and Muscular Disorders Research (66%)
Related topics:
Neurogenetic and Muscular Disorders Research (66%),
Pharmaceutical Economics and Policy (12%)
OpenAlex ID:
keywords/spinraza
Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy
2017
·
David R Corey
·
Nature Neuroscience
·
253
ISS-N1 makes the first FDA-approved drug for spinal muscular atrophy
2017
·
Eric W. Ottesen
·
Translational Neuroscience
·
187
PDF
Advances and limitations for the treatment of spinal muscular atrophy
2022
·
John W. Day
, Kelly Howell
, et al.
·
BMC Pediatrics
·
166
PDF
Pilot study of population-based newborn screening for spinal muscular atrophy in New York state
2017
·
Jennifer N. Kraszewski
, Denise M. Kay
, et al.
·
Genetics in Medicine
·
160
PDF
Current State of Human Gene Therapy: Approved Products and Vectors
2023
·
Aladdin Y. Shchaslyvyi
, Svitlana V. Antonenko
, et al.
·
Pharmaceuticals
·
128
PDF
Precision Medicine through Antisense Oligonucleotide-Mediated Exon Skipping
2018
·
Dunhui Li
, Frank L. Mastaglia
, et al.
·
Trends in Pharmacological Sciences
·
80
Clinical applications of gene therapy for rare diseases: A review
2023
·
Ioannis Papaioannou
, James S. Owen
, et al.
·
International Journal of Experimental Pathology
·
71
PDF
Spinraza—a rare disease success story
2017
·
V Prakash
·
Gene Therapy
·
50
PDF
Perspectives on Spinraza (Nusinersen) Treatment Study: Views of Individuals and Parents of Children Diagnosed with Spinal Muscular Atrophy
2018
·
Michelle Pacione
, Carly E. Siskind
, et al.
·
Journal of Neuromuscular Diseases
·
49
Base editing-mediated splicing correction therapy for spinal muscular atrophy
2020
·
Xiang Lin
, Haizhu Chen
, et al.
·
Cell Research
·
45
PDF
New treatments for serious conditions: ethical implications
2017
·
N M P King
, C E Bishop
·
Gene Therapy
·
40
Strategies of stratification: Regulating market access in the era of personalized medicine
2021
·
Sarah Wadmann
, Amalie Martinus Hauge
·
Social Studies of Science
·
39
Developmental regulation of SMN expression: pathophysiological implications and perspectives for therapy development in spinal muscular atrophy
2017
·
S Jablonka
, M Sendtner
·
Gene Therapy
·
37
RNA in spinal muscular atrophy: therapeutic implications of targeting
2020
·
Ravindra N. Singh
, Joonbae Seo
, et al.
·
Expert Opinion on Therapeutic Targets
·
30
Patient and family social media use surrounding a novel treatment for a rare genetic disease: a qualitative interview study
2020
·
Alexander A. Iyer
, Julie R. Barzilay
, et al.
·
Genetics in Medicine
·
24
Newborn screening for spinal muscular atrophy: The Wisconsin first year experience
2021
·
Mei W. Baker
, Sean T. Mochal
, et al.
·
Neuromuscular Disorders
·
22
Market access of Spinraza (Nusinersen) for spinal muscular atrophy: intellectual property rights, pricing, value and coverage considerations
2017
·
S Simoens
, I Huys
·
Gene Therapy
·
21
Development of the Method for Nusinersen and Its Metabolites Identification in the Serum Samples of Children Treated with Spinraza for Spinal Muscular Atrophy
2022
·
Sylwia Studzińska
, Maria Mazurkiewicz-Bełdzińska
, et al.
·
International Journal of Molecular Sciences
·
17
PDF
Identification of SRSF10 as a regulator of SMN2 ISS‐N1
2020
·
Sabrina B. Frederiksen
, Lise L. Holm
, et al.
·
Human Mutation
·
17
PDF
Evaluation of potential effects of Plastin 3 overexpression and low-dose SMN-antisense oligonucleotides on putative biomarkers in spinal muscular atrophy mice
2018
·
Eike A. Strathmann
, Miriam Peters
, et al.
·
PLoS ONE
·
17
PDF
ACTIVE (Ability Captured Through Interactive Video Evaluation) workspace volume video game to quantify meaningful change in spinal muscular atrophy
2019
·
Lindsay N Alfano
, Natalie F Miller
, et al.
·
Developmental Medicine & Child Neurology
·
16
Moving neuromuscular disorders research forward: from novel models to clinical studies
2020
·
Maaike van Putten
, Julija Hmeljak
, et al.
·
Disease Models & Mechanisms
·
14
PDF
Pricing of orphan drugs in oncology and rare diseases
2020
·
Mark Nuijten
, Stefano Capri
·
Journal of Market Access & Health Policy
·
14
PDF
Cure SMA and our patient community celebrate the first approved drug for SMA
2017
·
J Glascock
, M Lenz
, et al.
·
Gene Therapy
·
14
The impact of early phase price agreements on prices of orphan drugs
2021
·
Mark Nuijten
, Philippe Van Wilder
·
BMC Health Services Research
·
13
PDF
Show more works
View as search
Works count:
169
Citation count:
1,680
Year
Topic
Type